Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Q4 2019 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Q4 2019 earnings summary

9 Nov, 2026

Executive summary

  • Pre-revenue developer of programmed T-cell cancer therapies; no approved products or product-sales revenue in the 15-month period ended 31 December 2019.

  • Reporting period covers 15 months after the financial year-end changed from 30 September to 31 December; prior IFRS comparison covers 12 months.

Financial highlights

  • IFRS operating loss was £132.9m and net loss £113.5m for the 15-month period; prior 12-month losses were £40.4m and £31.1m, respectively.

  • R&D expense was £91.0m and administrative expense £41.3m; R&D included higher clinical study costs and share-based compensation.

  • Other operating income was £2.6m, finance income £7.0m and finance expense £1.7m; income tax credit was £14.1m.

  • Cash and cash equivalents were £159.3m at 31 December 2019, compared with £189.3m at 30 September 2018.

Outlook and guidance

  • Available cash, including the January 2020 financing, was expected to fund planned operating expenses and capital needs for at least 12 months; directors forecast cash extending into early 2022.

  • Significant expenses and operating losses expected to continue as candidates advance through clinical development, regulatory review and potential commercialization.

  • Planned milestones included AUTO1 adult ALL Phase 2 initiation in 2020, AUTO4 interim data in Q4 2020 and AUTO8 Phase 1 initiation in 2020.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics